Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Scynexis Inc (NQ: SCYX )

1.950 -0.080 (-3.94%)
Streaming Delayed Price Updated: 2:36 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Scynexis Inc

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
SCYNEXIS's Return On Capital Employed Overview
Via Benzinga
Scynexis Looks For Commercial Partner For Its Lead Infection Treatment
Via Benzinga
Scynexis Touts Postive Data For Ibrexafungerp For Vaginal Infections
Via Benzinga
Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
SCYNEXIS: Q1 Earnings Insights
SCYNEXIS (NASDAQ:SCYX) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday! 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 258 companies hit new 52-week lows. 
Via Benzinga
Looking Into SCYNEXIS's Return On Capital Employed
Benzinga Pro data, SCYNEXIS (NASDAQ:SCYX) reported Q2 sales of $1.32 million. Earnings fell to a loss of $13.35 million, resulting in a 144.82% decrease from last quarter. 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Earnings Scheduled For August 15, 2022
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings for its second quarter. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
SCYNEXIS Shares Climb As FDA Accepts Filing For Vaginal Yeast Infection Candidate Under Priority Review
SCYNEXIS (NASDAQ: SCYX) announced that the U.S. Food and Drug Administration (FDA) has accepted its submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME... 
Via Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022. 
Via Benzinga
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
Gainers Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year... 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million. 
Via Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For SCYNEXIS
SCYNEXIS (NASDAQ:SCYX) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement. Analysts estimate that SCYNEXIS will... 
Via Benzinga
Mid-Afternoon Market Update: Dow Dips Over 800 Points; HCA Healthcare Shares Plunge
U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 800 points on Friday. 
Via Benzinga
Earnings Scheduled For May 12, 2022
Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter. 
Via Benzinga
55 Biggest Movers From Friday
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate... 
Via Benzinga
Mid-Day Market Update: Nasdaq Down 200 Points; Blueknight Shares Spike Higher
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 200 points on Friday. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.